hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
table of contents valero energy corporation notes to consolidated financial statements ( continued ) 11 . equity share activity activity in the number of shares of common stock and treasury stock was as follows ( in millions ) : common treasury .

Table:
 | commonstock | treasurystock
balance as of december 31 2015 | 673 | -200 ( 200 )
transactions in connection withstock-based compensation plans | 2014 | 1
stock purchases under purchase program | 2014 | -23 ( 23 )
balance as of december 31 2016 | 673 | -222 ( 222 )
transactions in connection withstock-based compensation plans | 2014 | 1
stock purchases under purchase programs | 2014 | -19 ( 19 )
balance as of december 31 2017 | 673 | -240 ( 240 )
stock purchases under purchase programs | 2014 | -16 ( 16 )
balance as of december 31 2018 | 673 | -256 ( 256 )
preferred stock we have 20 million shares of preferred stock authorized with a par value of $ 0.01 per share .
no shares of preferred stock were outstanding as of december 31 , 2018 or 2017 .
treasury stock we purchase shares of our common stock as authorized under our common stock purchase program ( described below ) and to meet our obligations under employee stock-based compensation plans .
on july 13 , 2015 , our board of directors authorized us to purchase $ 2.5 billion of our outstanding common stock with no expiration date , and we completed that program during 2017 .
on september 21 , 2016 , our board of directors authorized our purchase of up to an additional $ 2.5 billion with no expiration date , and we completed that program during 2018 .
on january 23 , 2018 , our board of directors authorized our purchase of up to an additional $ 2.5 billion ( the 2018 program ) with no expiration date .
during the years ended december 31 , 2018 , 2017 , and 2016 , we purchased $ 1.5 billion , $ 1.3 billion , and $ 1.3 billion , respectively , of our common stock under our programs .
as of december 31 , 2018 , we have approval under the 2018 program to purchase approximately $ 2.2 billion of our common stock .
common stock dividends on january 24 , 2019 , our board of directors declared a quarterly cash dividend of $ 0.90 per common share payable on march 5 , 2019 to holders of record at the close of business on february 13 , 2019 .
valero energy partners lp units on september 16 , 2016 , vlp entered into an equity distribution agreement pursuant to which vlp offered and sold from time to time their common units having an aggregate offering price of up to $ 350 million based on amounts , at prices , and on terms determined by market conditions and other factors at the time of .

Question: if the same amount was spent monthly for 24 months purchasing $ 2.5 billion of common stock , what was the monthly average spent be , in billions?
Answer: 0.104
Calculation: divide(2.5, 24)
Defined Benefit Pension Plan Assets
The investments of the plans are managed by insurance companies or third-party investment managers selected by Autodesk's Trustees, consistent with regulations or market practice of the country where the assets are invested. Investments managed by qualified insurance companies or third-party investment managers under standard contracts follow local regulations, and Autodesk is not actively involved in their investment strategies.
Defined benefit pension plan assets measured at fair value on a recurring basis consisted of the following investment categories at the end of each period as follows:
The insurance contracts in the preceding table represent the immediate cash surrender value of assets managed by qualified insurance companies. Autodesk does not have control over the target allocation or visibility of the investment strategies of those investments. Insurance contracts and investments held by insurance companies made up 35% and 44% of total plan assets as of January 31, 2019 and January 31, 2018, respectively.
The assets held in the investment fund in the preceding table are invested in a diversified growth fund actively managed by Russell Investments in association with Aon Hewitt. The objective of the fund is to generate capital appreciation on a longterm basis through a diversified portfolio of investments. The fund aims to deliver equity-like returns in the medium to long term with around two-thirds the volatility of equity markets. The fair value of the assets held in the investment fund are priced monthly at net asset value without restrictions on redemption.
Table:
 | Fiscal Year Ended January 31, |  |  |  | 
 | 2019 |  |  |  | 2018
 | Level 1 | Level 2 | Level 3 | Total | Total
Insurance contracts | $— | $28.0 | $— | $28.0 | $53.0
Other investments | — | 14.5 | — | 14.5 | 17.0
Total assets measured at fair value | $— | $42.5 | $— | $42.5 | 70.0
Cash |  |  |  | 4.3 | 0.2
Investment Fund valued using net asset value |  |  |  | 34.0 | 50.9
Total pension plan assets at fair value |  |  |  | $80.8 | $121.1


Question: How are the assets in the investment fund priced?
Answer: The fair value of the assets held in the investment fund are priced monthly at net asset value without restrictions on redemption.
Free Cash Flow
The following provides a reconciliation of free cash flow, as used in this annual report, to its most directly comparable U.S. GAAP financial measures:
Management believes that the free cash flow measure provides useful information to investors regarding our financial condition because it is a measure of cash generated which management evaluates for alternative uses. It is management’s current intention to use excess cash to fund investments in capital equipment, acquisition opportunities and consistent dividend payments. Free cash flow is not a U.S. GAAP financial measure and should not be considered in isolation of, or as a substitute for, cash flows calculated in accordance with U.S. GAAP.
Table:
 |  | Fiscal Year | 
($ in millions) | 2019 | 2018 | 2017
Net cash provided from operating activities | $232.4 | $209.2 | $130.3
Purchases of property, plant, equipment and software | (180.3) | (135.0) | (98.5)
Acquisition of businesses, net of cash acquired | (79.0) | (13.3) | (35.3)
Proceeds from divestiture of business | — | — | 12.0
Proceeds from disposals of property, plant and equipment and assets held for sale | 0.4 | 1.9 | 2.5
Proceeds from note receivable from sale of equity method investment | — | 6.3 | 6.3
Proceeds from insurance recovery | 11.4 | — | —
Dividends paid | (38.6) | (34.4) | (34.1)
Free cash flow | $(53.7) | $34.7 | $(16.8)


Question: What was the Proceeds from insurance recovery in 2019?
Answer: 11.4
Lease liabilities regarding right-of-use assets are included on the balance sheet under “Borrowings”.
Extension and termination options are included in several leases in order to optimize operational flexibility in terms of managing contracts. The lease term determined by TORM is the noncancellable period of a lease, together with any extension/termination options if these are/are not reasonably certain to be exercised.
Table:
USDm | 2019 | 2018
Maturity analysis - contractual undiscounted cash flow |  | 
Less than one year | 7.5 | 5.2
One to five years | 27.6 | 25.6
More than five years | 0.1 | -
Total undiscounted lease liabilities as of 31 December | 35.2 | 30.8
Lease liabilities included under "Borrowings" as of 31 December | 30.6 | 25.3
Non-current | 10.2 | 3.2
Current | 20.4 | 22.1


Question: What is the lease term determined by TORM?
Answer: the noncancellable period of a lease, together with any extension/termination options if these are/are not reasonably certain to be exercised
9. Derivative Financial Instruments
As a global company, we are exposed in the normal course of business to interest rate and foreign currency risks that could affect our financial position, results of operations, and cash flows. We use derivative instruments to hedge against these risks and only hold such instruments for hedging purposes, not for speculative or trading purposes.
Depending on the terms of the specific derivative instruments and market conditions, some of our derivative instruments may be assets and others liabilities at any particular balance sheet date. We report all of our derivative instruments at fair value and account for changes in the fair value of derivative instruments within “Accumulated other comprehensive loss” if the derivative instruments qualify for hedge accounting. For those derivative instruments that do not qualify for hedge accounting (i.e., “economic hedges”), we record the changes in fair value directly to earnings. See Note 11. “Fair Value Measurements” to our consolidated financial statements for information about the techniques we use to measure the fair value of our derivative instruments.
The following tables present the fair values of derivative instruments included in our consolidated balance sheets as of December 31, 2019 and 2018 (in thousands):
Table:
 |  | December 31, 2019 |  | 
 | Prepaid Expenses and Other Current Assets | Other Assets | Other Current Liabilities | Other Liabilities
Derivatives designated as hedging instruments:    |  |  |  | 
Foreign exchange forward contracts | $226 | $139 | $369 | $230
Total derivatives designated as hedging instruments | $226 | $139 | $369 | $230
Derivatives not designated as hedging instruments: |  |  |  | 
Foreign exchange forward contracts | $973 | $— | $1,807 | $—
Interest rate swap contracts . | — | — | 406 | 7,209
Total derivatives not designated as hedging instruments . | $973 | $— | $2,213 | $7,209
Total derivative instruments . | $1,199 | $139 | $2,582 | $7,439


Question: What is the difference in the total derivative instruments between other assets and other current liabilities?
Answer: -2443
Calculation: 139-2,582
Note 8 – Property, Plant and Equipment
As of December 31, 2019 and 2018, property, plant and equipment was comprised of the following:
Depreciation expense was $12.5 million, $12.7 million and $12.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, which is recorded in cost of sales, selling, general and administrative expense and research and development expense in the consolidated statements of income.
We assess long-lived assets used in operations for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the undiscounted cash flows estimated to be generated by the asset are less than the asset’s carrying value. During the year ended December 31, 2019, the Company recognized impairment charges of $3.9 million related to the abandonment of certain information technology projects in which we had previously capitalized expenses related to these projects. The impairment charges were determined based on actual costs incurred as part of the projects. No impairment charges were recognized during the years ended December 31, 2018 and 2017.
Table:
(In thousands) | 2019 | 2018
Land | $4,575 | $4,575
Building and land improvements | 34,797 | 34,379
Building | 68,157 | 68,183
Furniture and fixtures | 19,959 | 19,831
Computer hardware and software | 74,399 | 92,071
Engineering and other equipment | 130,430 | 127,060
Total Property, Plant and Equipment | 332,317 | 346,099
Less accumulated depreciation | (258,609) | (265,464)
Total Property, Plant and Equipment, net | $73,708 | $80,635


Question: What was the change in furniture and fixtures between 2018 and 2019?
Answer: 128
Calculation: 19,959-19,831
As of December 31, 2019, exercisable options had an intrinsic value of less than $0.1 million. The intrinsic value of options exercised was $0.4 million in 2019 and $0.1 million in 2018. The following are the assumptions used in valuing the 2019 and 2018 stock option grants:
In January 2020, we issued options to employees for the purchase of up to 591,004 shares of common stock, at an exercise price of $1.23 per share which vest and become exercisable in four annual installments ending in January 2024. The options have a grant date fair value per share of $1.26.
Table:
Year Ended December 31 |  | 
 | 2019 | 2018
Assumed volatility | 64% - 69% | 75% - 81%
 | (67% weighted average) | (78% weighted average)
Assumed risk free interest rate | 1.8% - 2.7% | 2.2% - 2.8%
 | (2.4% weighted average) | (2.5% weighted average)
Average expected life of options (in years) | 6.1 - 6.3 | 6.2
 | (6.2 weighted average) | (6.2 weighted average)
Expected dividends | - | -


Question: As of December 31, 2019, what is the intrinsic value of the outstanding stock options?
Answer: $0.1 million
Stock Options
Our stock options are generally exercisable in increments of either one-fourth or one-third per year beginning one year from the date of grant. Stock options issued after February 2014 expire eight years from the date of grant. Options issued prior to February 2014 expire six years from the date of grant. Option activity for 2019 is summarized as follows:
The total intrinsic value was $108 million, $446 million, and $198 million for options exercised in 2019, 2018, and 2017, respectively.
Table:
 | Number of Shares | Weighted-Average Exercise Price Per Share | Weighted-Average Remaining Contractual Life (In Years) | Aggregate Intrinsic Value
Outstanding as of August 30, 2018 | 18 | $23.38 |  | 
Granted | — | 44.30 |  | 
Exercised | (5) | 17.50 |  | 
Canceled or expired | (1) | 22.60 |  | 
Outstanding as of August 29, 2019 | 12 | 25.94 | 4.3 | $220
Exercisable as of August 29, 2019 | 7 | $25.37 | 3.7 | $143
Unvested as of August 29, 2019 | 5 | 26.94 | 5.5 | 77


Question: What was the total intrinsic value for options exercised in 2018?
Answer: $446 million
Comprehensive Income — Comprehensive income includes net income, currency translation adjustments, certain derivative-related activity, changes in the value of available-for-sale investments (prior to the adoption of Accounting Standards Update ("ASU") 2016-01), and changes in prior service cost and net actuarial gains (losses) from pension (for amounts not in excess of the 10% "corridor") and postretirement health care plans. On foreign investments we deem to be essentially permanent in nature, we do not provide for taxes on currency translation adjustments arising from converting an investment denominated in a foreign currency to U.S. dollars. When we determine that a foreign investment, as well as undistributed earnings, are no longer permanent in nature, estimated taxes will be provided for the related deferred tax liability (asset), if any, resulting from currency translation adjustments.
The following table details the accumulated balances for each component of other comprehensive income, net of tax:
1 Net of unrealized gains on available-for-sale securities reclassified to retained earnings as a result of the adoption of ASU 2016-01 in fiscal 2019 and net of stranded tax effects from change in tax rate as a result of the early adoption of ASU 2018-02 in fiscal 2018 in the amount of $0.6 million and $17.4 million, respectively.
Notes to Consolidated Financial Statements - (Continued) Fiscal Years Ended May 26, 2019, May 27, 2018, and May 28, 2017 (columnar dollars in millions except per share amounts)
Table:
 | 2019 | 2018 | 2017
Currency translation losses, net of reclassification adjustments | $(90.9) | $(94.7) | $(98.6)
Derivative adjustments, net of reclassification adjustments | 34.0 | 1.0 | (1.1)
Unrealized gains (losses) on available-for-sale securities | — | 0.6 | (0.3)
Pension and post-employment benefit obligations, net of reclassification adjustments | (53.4) | (17.4) | (112.9)
Accumulated other comprehensive loss 1 | $(110.3) | $(110.5) | $(212.9)


Question: What is the percentage change of accumulated other comprehensive loss in 2018 compared to 2017?
Answer: -48.1
Calculation: (-110.5-(-212.9))/(-212.9)
xvii. Transfer of unclaimed/unpaid amounts to the Investor Education and Protection Fund:
Pursuant to Sections 124 and 125 of the Act read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (“IEPF Rules”), dividend, if not claimed for a consecutive period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund (“IEPF”).
Further, all the shares in respect of which dividend has remained unclaimed for seven consecutive years or
more from the date of transfer to unpaid dividend account shall also be transferred to IEPF Authority. The said
requirement does not apply to shares in respect of which there is a specific order of Court, Tribunal or Statutory
Authority, restraining any transfer of the shares.
In the interest of the shareholders, the Company sends periodical reminders to the shareholders to claim
their dividends in order to avoid transfer of dividends/shares to IEPF Authority. Notices in this regard are also
published in the newspapers and the details of unclaimed dividends and shareholders whose shares are liable
to be transferred to the IEPF Authority, are uploaded on the Company’s website (https://www.tcs.com/detailsunclaimed-
dividend-transfer-IEPF-account-2017).
In light of the aforesaid provisions, the Company has during the year under review, transferred to IEPF the
unclaimed dividends, outstanding for 7 consecutive years, of the Company, erstwhile TCS e-Serve Limited and
CMC Limited (since amalgamated with the Company). Further, shares of the Company, in respect of which
dividend has not been claimed for 7 consecutive years or more from the date of transfer to unpaid dividend
account, have also been transferred to the demat account of IEPF Authority.
The details of unclaimed dividends and shares transferred to IEPF during FY 2019 are as follows:
* Includes final dividend of erstwhile TCS e-Serve Limited and erstwhile CMC Limited
The members who have a claim on above dividends and shares may claim the same from IEPF Authority by
submitting an online application in the prescribed Form No. IEPF-5 available on the website www.iepf.gov.
in and sending a physical copy of the same, duly signed to the Company, along with requisite documents
enumerated in the Form No. IEPF-5. No claims shall lie against the Company in respect of the dividend/shares
so transferred. The Members/Claimants can file only one consolidated claim in a financial year as per the IEPF
Rules.
Table:
Financial year | Amount of unclaimed dividend transferred (` lakh) | Number of shares transferred
2011 | 102.6* | 3,028
2012 | 86.5 | 29,672
TOTAL | 189.1 | 32,000


Question: How many shares from FY 2012 were transferred to IEPF in FY 2019?
Answer: 29,672
For purposes of reconciling the Company’s provision for income taxes at the statutory rate and the Company’s provision (benefit) for income taxes at the effective tax rate, a notional 26% tax rate was applied as follows (in thousands):
The difference between the statutory federal income tax rate and the Company’s effective tax rate in 2019, 2018 and 2017 is primarily attributable to the effect of state income taxes, difference between the U.S. and foreign tax rates, deferred tax state rate adjustment, share-based compensation, true up of deferred taxes, other non-deductible permanent items, and change in valuation allowance. In addition, the Company’s foreign subsidiaries are subject to varied applicable statutory income tax rates for the periods presented.
Table:
 |  | Year Ended December 31, | 
 | 2019 | 2018 | 2017
Income tax at federal statutory rate | $(10,883) | $(9,811) | $(6,659)
Increase (decrease) in tax resulting from: |  |  | 
State income tax expense, net of federal tax effect | (3,657) | (2,749) | (421)
Nondeductible permanent items | 3,522 | (1,522) | 1,506
Foreign rate differential | (367) | 552 | 599
Tax rate change | — | 134 | 7,226
Adjustment to deferred taxes | (1,904) | 307 | 37
Change in valuation allowance | 22,481 | 15,805 | (2,291)
Uncertain tax positions | 128 | 143 | 76
Nonqualified stock option and performance award windfall upon exercise | (9,128) | (1,983) | —
Other | 233 | (80) | (26)
Total | $425 | $796 | $47


Question: What is the average Nondeductible permanent items from 2017-2019?
Answer: 1168.67
Calculation: (3,522 - 1,522 + 1,506) / 3
Item 10. Directors, Executive Officers and Corporate Governance.
Executive Officers and Directors
The following sets forth certain information with respect to our executive officers and directors..
Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus
Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan
Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and
pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of
research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of
Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits
to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine
Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology
Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr.
Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National
Laboratories in Long Island, NY. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as
years of expertise in the financial and biopharmaceutical arenas.
Table:
Name | Age | Position (s)
Garo H. Armen | 67 | Executive Chairman of the Board of Directors
Alexander K. Arrow | 49 | Chief Financial Officer
Robert B. Stein | 69 | Director
Khalil Barrage | 55 | Director
Brian J. Corvese | 62 | Director
Josh Silverman | 49 | Director


Question: Who is the Chief Financial Officer of the company?
Answer: Alexander K. Arrow